Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
BMS axes bispecific months after filing to run phase 3 trial
BMS had had a whiplash change of heart on a BCMA bispecific T-cell engager, halting further development months after filing to run a phase 3 trial.
Nick Paul Taylor
Jul 26, 2024 8:17am
Sponsored
Cell and gene therapies: Navigating the cold chain revolution
Jul 22, 2024 8:00am
AbbVie axes Alzheimer's program amid 'evolving landscape'
Jul 25, 2024 10:49am
Sponsored
InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease
Jul 22, 2024 8:00am
Dexcom down 40% after CGM sales challenges
Jul 26, 2024 11:30am
Fierce Biotech Fundraising Tracker: Confo, Autobahn & more
Jul 26, 2024 10:00am
Medtech News
Abbott recalls some CGM sensors after inaccurate readings
Jul 25, 2024 2:00pm
Edwards inks $1.6B in deals for JenaValve, Endotronix
Jul 25, 2024 11:00am
Boston Scientific’s pulsed field ablation brings 125% EP growth
Jul 24, 2024 10:35am
FDA's device center director, Jeff Shuren, to retire
Jul 24, 2024 12:00am
See More Medtech News